A PYMNTS Company

US: Allergan fights Valeant with its own mega-merger

By  |  November 6, 2014

Pharmaceutical conglomerate Allergan, in efforts to avoid a takeover by Valeant Pharmaceuticals, is reportedly seeking to merge with fellow pharma-giant Actavis.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Unnamed sources say Allergan, which manufactures Botox, is in active discussions with Actavis, though the sources noted that a deal is not guaranteed. Allergan revealed in a filing Thursday that it is in discussions with a third party about a separate merger, though did not specify with which company.

    Allergan is looking to avoid a hostile takeover by Valeant in a deal valued at about $54 billion. The Botox maker has slammed the deal as “grossly inadequate” and has claimed the Canadian firm would severely cut Allergan’s research and development operations.

    Full content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.